Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy.

Sainio MT, Ylikallio E, Mäenpää L, Lahtela J, Mattila P, Auranen M, Palmio J, Tyynismaa H.

Neurol Genet. 2018 Jun 5;4(3):e244. doi: 10.1212/NXG.0000000000000244. eCollection 2018 Jun.

2.

Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

Murtola TJ, Vihervuori VJ, Lahtela J, Talala K, Taari K, Tammela TL, Auvinen A.

Br J Cancer. 2018 May;118(9):1248-1254. doi: 10.1038/s41416-018-0055-4. Epub 2018 Mar 22.

PMID:
29563633
3.

Spatial aspects of oncogenic signalling determine the response to combination therapy in slice explants from Kras-driven lung tumours.

Närhi K, Nagaraj AS, Parri E, Turkki R, van Duijn PW, Hemmes A, Lahtela J, Uotinen V, Mäyränpää MI, Salmenkivi K, Räsänen J, Linder N, Trapman J, Rannikko A, Kallioniemi O, Af Hällström TM, Lundin J, Sommergruber W, Anders S, Verschuren EW.

J Pathol. 2018 May;245(1):101-113. doi: 10.1002/path.5059. Epub 2018 Apr 2.

4.

Re-organizing inpatient care saves legs in patients with diabetic foot infections.

Laakso M, Honkasalo M, Kiiski J, Ala-Houhala M, Haapasalo H, Laine HJ, Luukkaala T, Lahtela J, Kaartinen I.

Diabetes Res Clin Pract. 2017 Mar;125:39-46. doi: 10.1016/j.diabres.2017.01.007. Epub 2017 Jan 22.

PMID:
28167324
5.

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.

Nagaraj AS, Lahtela J, Hemmes A, Pellinen T, Blom S, Devlin JR, Salmenkivi K, Kallioniemi O, Mäyränpää MI, Närhi K, Verschuren EW.

Cell Rep. 2017 Jan 17;18(3):673-684. doi: 10.1016/j.celrep.2016.12.059.

6.

The Long-term Prospective Follow-up of Pancreatic Function After the First Episode of Acute Alcoholic Pancreatitis: Recurrence Predisposes One to Pancreatic Dysfunction and Pancreatogenic Diabetes.

Nikkola J, Laukkarinen J, Lahtela J, Seppänen H, Järvinen S, Nordback I, Sand J.

J Clin Gastroenterol. 2017 Feb;51(2):183-190. doi: 10.1097/MCG.0000000000000564.

PMID:
28060789
7.

Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer.

Kilpeläinen TP, Mäkinen T, Karhunen PJ, Aro J, Lahtela J, Taari K, Talala K, Tammela TL, Auvinen A.

Cancer Epidemiol. 2016 Dec;45:1-5. doi: 10.1016/j.canep.2016.08.022. Epub 2016 Sep 14.

PMID:
27636505
8.

Obesity paradox disappears in coronary artery bypass graft patients during 20-year follow-up.

Hällberg V, Kataja M, Lahtela J, Tarkka M, Inamaa T, Palomäki A; W-CABG Study Group.

Eur Heart J Acute Cardiovasc Care. 2017 Dec;6(8):771-777. doi: 10.1177/2048872616633844. Epub 2016 Feb 24.

PMID:
26912911
9.

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.

Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornøe K, Boopalan A, Nauck MA; NN2211-3917 Study Group.

Diabetes Obes Metab. 2015 Nov;17(11):1056-64. doi: 10.1111/dom.12539. Epub 2015 Sep 10.

10.

The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis.

Lahtela J, Pradhan B, Närhi K, Hemmes A, Särkioja M, Kovanen PE, Brown A, Verschuren EW.

Dis Model Mech. 2015 Apr;8(4):393-401. doi: 10.1242/dmm.019257. Epub 2015 Feb 20.

11.

Associations of metabolic syndrome and diabetes mellitus with 16-year survival after CABG.

Hällberg V, Palomäki A, Lahtela J, Voutilainen S, Tarkka M, Kataja M; Study Group (W-CABG).

Cardiovasc Diabetol. 2014 Jan 22;13:25. doi: 10.1186/1475-2840-13-25.

12.

Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries.

Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, Lahtela J, Jensen MM, Östenson CG.

J Med Econ. 2013 Dec;16(12):1453-61. doi: 10.3111/13696998.2013.852098. Epub 2013 Oct 25.

PMID:
24144009
13.

Self-reported non-severe hypoglycaemic events in Europe.

Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U.

Diabet Med. 2014 Jan;31(1):92-101. doi: 10.1111/dme.12261. Epub 2013 Jul 26.

14.

Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial.

Pakarinen TK, Laine HJ, Mäenpää H, Kähönen M, Mattila P, Lahtela J.

Foot Ankle Surg. 2013 Jun;19(2):121-4. doi: 10.1016/j.fas.2012.12.007. Epub 2013 Feb 20.

PMID:
23548455
15.

A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3.

Lahtela J, Corson LB, Hemmes A, Brauer MJ, Koopal S, Lee J, Hunsaker TL, Jackson PK, Verschuren EW.

Cell Cycle. 2013 Feb 15;12(4):625-34. doi: 10.4161/cc.23515. Epub 2013 Jan 16.

16.

Lethal evolution of a newborn with consistent features of hydrolethalus syndrome--Romanian patient.

Belengeanu V, Viskari H, Tallila J, Lahtela J, Farcas S, Andreescu N, Stoian M, Bohiltea CL, Fryns JP.

Genet Couns. 2011;22(3):293-304.

PMID:
22029171
17.

The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.

Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J.

Diabetes Care. 2011 Jul;34(7):1514-6. doi: 10.2337/dc11-0396. Epub 2011 May 18.

18.

[Hyponatremia due to psychoactive drugs is common in the elderly].

Alanen HM, Lahtela J, Leinonen E.

Duodecim. 2011;127(4):406-13. Review. Finnish.

PMID:
21442861
19.

Mutant CHUK and severe fetal encasement malformation.

Lahtela J, Nousiainen HO, Stefanovic V, Tallila J, Viskari H, Karikoski R, Gentile M, Saloranta C, Varilo T, Salonen R, Kestilä M.

N Engl J Med. 2010 Oct 21;363(17):1631-7. doi: 10.1056/NEJMoa0911698.

20.

Long-term outcome and quality of life in patients with Charcot foot.

Pakarinen TK, Laine HJ, Mäenpää H, Mattila P, Lahtela J.

Foot Ankle Surg. 2009;15(4):187-91. doi: 10.1016/j.fas.2009.02.005. Epub 2009 Apr 5.

PMID:
19840750
21.

Unraveling the disease pathogenesis behind lethal hydrolethalus syndrome revealed multiple changes in molecular and cellular level.

Honkala H, Lahtela J, Fox H, Gentile M, Pakkasjärvi N, Salonen R, Wartiovaara K, Jauhiainen M, Kestilä M.

Pathogenetics. 2009 Apr 28;2(1):2. doi: 10.1186/1755-8417-2-2.

22.

Analysis of cardiovascular responses to passive head-up tilt using continuous pulse wave analysis and impedance cardiography.

Tahvanainen A, Koskela J, Tikkakoski A, Lahtela J, Leskinen M, Kähönen M, Nieminen T, Kööbi T, Mustonen J, Pörsti I.

Scand J Clin Lab Invest. 2009;69(1):128-37. doi: 10.1080/00365510802439098.

PMID:
18850486
23.

Antidiabetic medication and prostate cancer risk: a population-based case-control study.

Murtola TJ, Tammela TL, Lahtela J, Auvinen A.

Am J Epidemiol. 2008 Oct 15;168(8):925-31. doi: 10.1093/aje/kwn190. Epub 2008 Aug 11.

PMID:
18700234
24.

Statins and prostate cancer prevention: where we are now, and future directions.

Murtola TJ, Visakorpi T, Lahtela J, Syvälä H, Tammela TLj.

Nat Clin Pract Urol. 2008 Jul;5(7):376-87. doi: 10.1038/ncpuro1146. Epub 2008 Jun 10. Review.

PMID:
18542103
25.

Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study.

Ilanne-Parikka P, Eriksson JG, Lindström J, Peltonen M, Aunola S, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, Valle TT, Lahtela J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Diabetes Care. 2008 Apr;31(4):805-7. doi: 10.2337/dc07-1117. Epub 2008 Jan 9.

PMID:
18184907
26.

Peripheral vascular disease in diabetic peritoneal dialysis patients.

Saha HH, Leskinen YK, Salenius JP, Lahtela JT.

Perit Dial Int. 2007 Jun;27 Suppl 2:S210-4. Review.

PMID:
17556307
27.

Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study.

Murtola TJ, Tammela TL, Lahtela J, Auvinen A.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2226-32.

28.

Assessment of causes of death in a prostate cancer screening trial.

Mäkinen T, Karhunen P, Aro J, Lahtela J, Määttänen L, Auvinen A.

Int J Cancer. 2008 Jan 15;122(2):413-7.

29.

Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort.

Ilanne-Parikka P, Eriksson JG, Lindström J, Hämäläinen H, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Rastas M, Salminen V, Aunola S, Sundvall J, Valle T, Lahtela J, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study Group.

Diabetes Care. 2004 Sep;27(9):2135-40.

PMID:
15333474
30.

The Finnish trial of prostate cancer screening: where are we now?

Finne P, Stenman UH, Määttänen L, Mäkinen T, Tammela TL, Martikainen P, Ruutu M, Ala-Opas M, Aro J, Karhunen PJ, Lahtela J, Rissanen P, Juusela H, Hakama M, Auvinen A.

BJU Int. 2003 Dec;92 Suppl 2:22-6. No abstract available.

31.

Natriuretic peptide and echocardiography after operation of atrial septal defect.

Groundstroem KW, Iivainen TE, Lahtela JT, Talvensaari TJ, Paakkala TA, Pasternack AI, Uusitalo AJ.

Int J Cardiol. 2003 May;89(1):45-52.

PMID:
12727004
32.

Telemedical devices in diabetes management.

Lahtela JT, Lamminen H.

Ann Med. 2002;34(4):241-7. Review.

PMID:
12371708
33.

Charcot arthropathy of the diabetic foot. Current concepts and review of 36 cases.

Pakarinen TK, Laine HJ, Honkonen SE, Peltonen J, Oksala H, Lahtela J.

Scand J Surg. 2002;91(2):195-201. Review.

PMID:
12164523
34.

[Multi-injection insulin therapy using two basic insulin components--an alternative towards a better glycemic control].

Lahtela J, Nevalainen P.

Duodecim. 1998;114(19):1949-53. Finnish. No abstract available.

PMID:
11717748
35.

[Ill from eating salad].

Lahtela J, Tuomi ML, Karvonen AL.

Duodecim. 1998;114(6):551-3. Finnish. No abstract available.

PMID:
11466918
36.

Costs of treating deep-vein thrombosis.

Collin P, Pietilä K, Lahtela J.

QJM. 2001 May;94(5):284-5. No abstract available.

PMID:
11353105
37.

Hepatic subcapsular steatosis in diabetic CAPD patients treated with intraperitoneal insulin. Description of a typical pattern.

Kallio T, Nevalainen PI, Lahtela JT, Mustonen J, Pasternack A.

Acta Radiol. 2001 May;42(3):323-5.

PMID:
11350293
38.

High peritoneal permeability predisposes to hepatic steatosis in diabetic continuous ambulatory peritoneal dialysis patients receiving intraperitoneal insulin.

Nevalainen PI, Kallio T, Lahtela JT, Mustonen J, Pasternack AI.

Perit Dial Int. 2000 Nov-Dec;20(6):637-42.

PMID:
11216552
39.

Serum N-terminal atrial natriuretic peptide in adult patients late after surgical repair of atrial septal defect.

Iivainen TE, Groundstroem KW, Lahtela JT, Talvensaari TJ, Pasternack A, Uusitalo A.

Eur J Heart Fail. 2000 Jun;2(2):161-5.

40.

Intraperitoneal insulin reduces plasma leptin concentration in diabetic patients on CAPD.

Nevalainen PI, Lahtela JT, Mustonen J, Pasternack A.

Perit Dial Int. 2000 Jan-Feb;20(1):27-32.

PMID:
10716580
41.

No effect of gluten-free diet on the metabolic control of type 1 diabetes in patients with diabetes and celiac disease. Retrospective and controlled prospective survey.

Kaukinen K, Salmi J, Lahtela J, Siljamäki-Ojansuu U, Koivisto AM, Oksa H, Collin P.

Diabetes Care. 1999 Oct;22(10):1747-8. No abstract available.

PMID:
10526749
42.

The effect of insulin delivery route on lipoproteins in type I diabetic patients on CAPD.

Nevalainen PI, Lahtela JT, Mustonen J, Taskinen MR, Pasternack A.

Perit Dial Int. 1999 Mar-Apr;19(2):148-53.

PMID:
10357186
43.

Late postoperative follow-up of ostium secundum defect.

Groundstroem KW, Iivainen TE, Talvensaari T, Lahtela JT.

Eur Heart J. 1999 Jun;20(12):904-9.

PMID:
10329097
44.

Effect of acetaldehyde and acetylsalicylic acid on HbA1c chromatography in the FPLC method with Mono S cation exchanger.

Koskinen LK, Korpela MM, Lahtela JT, Laippala PJ, Pikkarainen PH, Koivula TA.

Clin Chim Acta. 1998 Jul 6;275(1):53-61.

PMID:
9706843
45.

Does uremia interfere with HbA1c results in the FPLC method with Mono S cation exchanger?

Koskinen LK, Ala-Houhala IO, Lahtela JT, Laippala PJ, Koivula TA.

Clin Chim Acta. 1998 May 8;273(1):69-79.

PMID:
9620471
46.

Insulin sensitivity in a long-term crossover trial with celiprolol and other antihypertensive agents.

Malminiemi K, Lahtela J, Malminiemi O, Ala-Kaila K, Huupponen R.

J Cardiovasc Pharmacol. 1998 Jan;31(1):140-5.

PMID:
9456288
47.

Effect of nasal CPAP treatment on insulin sensitivity and plasma leptin.

Saarelainen S, Lahtela J, Kallonen E.

J Sleep Res. 1997 Jun;6(2):146-7. No abstract available.

48.

Severe antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. A case report.

Lahtela JT, Knip M, Paul R, Antonen J, Salmi J.

Diabetes Care. 1997 Jan;20(1):71-3.

PMID:
9028697
49.
50.

Pulmonary involvement in nephropathia epidemica: radiological findings and their clinical correlations.

Kanerva M, Paakkala A, Mustonen J, Paakkala T, Lahtela J, Pasternack A.

Clin Nephrol. 1996 Dec;46(6):369-78.

PMID:
8982552

Supplemental Content

Loading ...
Support Center